Morice et al.[24] |
19 |
Nebulized budesonide -2 mg bid Oral prednisolone -30 mg OD |
Clinical efficacy was similar in both the groups |
Urinary steroid metabolites were higher in budesonide group |
Maltais et al.[25] |
199 |
Nebulized budesomde -2 mg 6 hrly Oral prednisolone -30 mg 12 hrly Placebo |
FEV1 improvement was similar to oral prednisolone Borg scale rating was similar in both groups |
Higher incidence of hyperglycemia with oral prednisolone |
Mirici et al.[26] |
40 |
Nebulized budesomde -8 mg daily IV Preddnisolone -40 mg OD |
Similar clinical efficacy as parental steroids in expiratory flow rates, PaO2 PaCO2 and SaO2, values |
Minimal side effects |
Gunen et al.[15,27] |
159 |
Nebulized budesomde -1.5 mg 6 hrly Oral prednisolone -40 mg OD Standard bronchodilator therapy |
Significant improvement in FVC, FEV1 FEF25-75% and PaO2 in budesonide group Relapse and re-hospitalization rates were reduced by half in budesonide group |
Hyperglycemia in oral prednisolone group |
Wei et al.[28] |
60 |
Nebulized budesomde Oral prednisolone Control group |
Dyspnea score, FEV1 and improvement in ABG were significantly better in budesonide group |
Mmimal side effects |
Guozhong et al.[29] |
40 |
Nebulized budesomde Control group |
Better improvement in FEV1 and PaO2 values in budesonide group |
Nil |
Marcus et al.[30] |
25 |
Budesomde suspension -0.5 mg 12 hrly MDI/DPI |
Reduction in exacerbation rates Improvement in FEV1, better symptom control, increased confidence with budesonide |
Minimal side effects |
Gaude and Nemagouda[31] |
125 |
Nebulized budesonide -2 mg bid IV Hydrocortisone -100 mg 6 hrly |
Spirometry variables, SpO2 improvement similar in both groups |
Minimal side effects |
|
|
|
HRQL score better improved with budesonide Duration of hospitalization shorter in budesomde group |
|